{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026709","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.387756+00:00","generated_at":"2026-06-18T19:48:42.143818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novavax reports Q4 2022 revenue $357M, net loss $182M; raises going concern doubt","bullets":["Q4 revenue $357M (+61% YoY), full year $1.9B (+73% YoY); net loss Q4 $182M, full year $658M.","Cash $1.3B as of Dec 31, 2022; raised $250M in convertible notes and equity in Dec 2022.","Appointed John C. Jacobs as President and CEO; raised going concern doubt about ability to continue through next year.","Updated US government agreement for up to 1.5M additional doses in 2023; initiated Phase 2 trial for COVID-19-Influenza combo vaccine.","Expanded Nuvaxovid label in adult booster and adolescent primary series."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026709","json":"https://secwatch.observer/filing/0001104659-23-026709.json","markdown":"https://secwatch.observer/filing/0001104659-23-026709.md","text":"https://secwatch.observer/filing/0001104659-23-026709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/tm237994d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T19:48:42.143818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0af6437e0081b2f0eb68248324747826b55423ca","claim":"NOVAVAX INC reported full year 2022 results: revenue $1.9 billion.","evidence_excerpt":"Total revenue for the full year 2022 was $1.9 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$1.9 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7fb1c0b266c27c8e261c9b7d2623bf329b114578","claim":"NOVAVAX INC reported fourth quarter 2022 results: revenue $357 million.","evidence_excerpt":"Total revenue for the fourth quarter 2022 was $357 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2022"},{"label":"Revenue","value":"$357 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}